AYTU logo

AYTU
Aytu BioPharma Inc

40,831
Mkt Cap
$22.75M
Volume
131,248.00
52W High
$2.82
52W Low
$0.95
PE Ratio
-0.82
AYTU Fundamentals
Price
$2.30
Prev Close
$2.30
Open
$2.27
50D MA
$2.24
Beta
0.69
Avg. Volume
306,723.62
EPS (Annual)
-$2.16
P/B
1.09
Rev/Employee
$799,783.13
Loading...
Loading...
News
all
press releases
New Strong Sell Stocks for Oct. 13th
AYTU, ALK and CNM have been added to the Zacks Rank #5 (Strong Sell) List on October 13, 2025.
Zacks·11d ago
News Placeholder
More News
News Placeholder
Dow Futures Gain Ahead Of Jerome Powell’s Speech: BA, HOLO, BETR, CLSK Among Stocks To Watch
While Dow Jones futures were up 0.13% at the time of writing, the S&P 500 futures edged lower by 0.03%.
Stocktwits·1mo ago
News Placeholder
Agilent Technologies (A) Surpasses Q3 Earnings and Revenue Estimates
Agilent (A) delivered earnings and revenue surprises of +0.74% and +4.60%, respectively, for the quarter ended July 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
News Placeholder
Aytu BioPharma's Earnings: A Preview
read more...
Benzinga·1y ago
News Placeholder
Presenting on the Emerging Growth Conference 69 Day 2 on April 4 Register Now
MIAMI, April 03, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 69th Emerging Growth Conference on April 3 & 4, 2024. The...
Globe Newswire·2y ago
News Placeholder
Presenting on the Emerging Growth Conference 69 Day 1 on April 3 Register Now
MIAMI, April 02, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 69th Emerging Growth Conference on April 3 & 4, 2024...
Globe Newswire·2y ago
News Placeholder
Aytu BioPharma, Inc. (NASDAQ:AYTU) Surges 25% Yet Its Low P/S Is No Reason For Excitement
Despite an already strong run, Aytu BioPharma, Inc. ( NASDAQ:AYTU ) shares have been powering on, with a gain of 25% in...
Simply Wall St·2y ago
News Placeholder
Aytu BioPharma Reports Record ADHD Revenue and Operating Income During Fiscal 2024 Second Quarter
Q2 2024 operating income of $2.4 millionQ2 2024 net loss of $0.2 million and adjusted EBITDA1 of $5.1 millionQ2 2024 Rx Segment net revenue of $18.7 million, net income of $0.7 million, and adjusted...
Accesswire·2y ago
News Placeholder
Aytu BioPharma to Report Second Quarter Fiscal 2024 Financial and Operational Results on February 14, 2024
DENVER, CO / ACCESSWIRE / February 7, 2024 / Aytu BioPharma, Inc. (the 'Company' or 'Aytu') (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its...
Accesswire·2y ago
News Placeholder
Does Aytu BioPharma (NASDAQ:AYTU) Have A Healthy Balance Sheet?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Simply Wall St·2y ago

Latest AYTU News

View

Advertisement|Remove ads.

Advertisement|Remove ads.